From 'Bad Pharma' to better guidance?

Cardiovascular Endocrinology

Volumn 2, Issue 1, 2013, Pages 1-3

  Krentz, Andrew J ^a  

^a UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ROSIGLITAZONE;

CLINICAL DECISION MAKING; CLINICAL MEDICINE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; HUMAN; MEDICAL INFORMATION; MEDICAL SOCIETY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; TRUST;

EID: 84938526162     PISSN: None     EISSN: 2162688X     Source Type: Journal    
DOI: 10.1097/XCE.0b013e32835fdee7     Document Type: Editorial

References (3)

1. Goldacre B. Bad Pharma: how drug companies mislead doctors and harm patients. London: HarperCollins; 2012.
2. Available at: http://www.pharmatimes.com/Article/13-02-06/ GSK-backs-AllTrials-campaign.aspx [Accessed 5 February 2013].
3. Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs 2011; 71: 123-130.